A Ferroptosis molecular subtype‐related signature for predicting prognosis and response to chemotherapy in patients with chronic lymphocytic leukemia

H Gong, H Li, Q Yang, G Zhang, H Liu… - BioMed Research …, 2022 - Wiley Online Library
Ferroptosis is a type of regulated cell death catalyzed by the iron‐dependent accumulation
of lipid hydroperoxides to lethal levels. Chronic lymphocytic leukemia (CLL) is a chronic …

Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction

A Landeira-Viñuela, C Arias-Hidalgo… - Frontiers in …, 2022 - frontiersin.org
Chronic lymphocytic leukemia (CLL) is a lymphoid neoplasm characterized by the
accumulation of mature B cells. The diagnosis is established by the detection of monoclonal …

Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents

A Galitzia, M Maccaferri, FR Mauro, R Murru… - Cancers, 2024 - mdpi.com
Simple Summary Targeted agents, such as Bruton's Tyrosine Kinase inhibitors and BCL-2
inhibitors, have transformed the treatment landscape for Chronic Lymphocytic Leukemia …

Immune Dysfunction and Infection–Interaction between CLL and Treatment: A Reflection on Current Treatment Paradigms and Unmet Needs

E Gargiulo, RS Teglgaard, T Faitová… - Acta Haematologica, 2023 - karger.com
Immune dysfunction and infection - interaction between CLL and treatment A reflection on
current treatment paradigms and unmet n Page 1 1 Acta Haematol , DOI: 10.1159/000533234 …

Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis

R Murru, A Galitzia, L Barabino, R Presicci… - Annals of …, 2024 - Springer
Abstract Chronic Lymphocytic Leukemia (CLL) is well-known for increasing susceptibility to
infections. Factors such as immune dysregulation, IGHV status, hypogammaglobulinemia …

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib

C Vitale, JL Gibbons, A Ferrajoli - OncoTargets and therapy, 2021 - Taylor & Francis
In chronic lymphocytic leukemia (CLL), a deeper understanding of the disease biology led
over the last decade to the development and clinical use of different targeted drugs …

Systematic Evaluation of Antigenic Stimulation in Chronic Lymphocytic Leukemia: Humoral Immunity as Biomarkers for Disease Evolution

A Landeira-Viñuela, M Alcoceba-Sanchez… - Cancers, 2023 - mdpi.com
Simple Summary Clonal B cell expansion in chronic lymphocytic leukemia may be triggered
by persistent antigenic stimulation. Therefore, studying the dynamics of the humoral …

[HTML][HTML] CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep?

C Vitale, V Griggio, F Perutelli, M Coscia - HemaSphere, 2023 - journals.lww.com
The clinical development of chimeric antigen receptor (CAR) T-cell therapy has been more
challenging for chronic lymphocytic leukemia (CLL) compared to other settings. One of the …

[PDF][PDF] 利妥昔单抗减量的FCR 方案一线治疗慢性淋巴细胞白血病疗效分析

罗菁, 张佼佼, 张兴利, 陈丽, 糜坚青 - 临床血液学杂志, 2022 - lcxyen.whuhzzs.com
利妥昔单抗减量的FCR方案一线治疗慢性淋巴细胞白血病疗效分析 Page 1 2022年 临床血液学
杂志 35卷9期 JClinHematol(China) 引用本文:罗菁,张佼佼,张兴利,等.利妥昔单抗减量的FCR方案 …

Demyelinating Polyradiculoneuropathy in Chronic Lymphocytic Leukemia: A Case Report on BTKis versus Venetoclax-Rituximab

A Cellini, A Visentin, A Salvalaggio, M Cacciavillani… - Hemato, 2023 - mdpi.com
The dysregulation of the immune system in Chronic Lymphocytic Leukemia (CLL) often
allows for the development of immune-mediated diseases. Among them, autoimmune …